Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

787.96 +8.29 (+1.06%)
Streaming Delayed Price Updated: 2:03 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
49 50 Next >
News headline image
Regeneron Pharmaceuticals Unusual Options Activity For April 25 ↗
 
Via Benzinga
News headline image
Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea ↗
 
Via Benzinga
News headline image
Regeneron Pharmaceuticals Unusual Options Activity For April 20 ↗
 
Via Benzinga
News headline image
The Greatest 7 Blue-Chip Stocks to Buy for Your Portfolio ↗
With so many rumblings in the equities space, investors may be best served taking on the top blue-chip stocks to buy. 
Via InvestorPlace
News headline image
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Regeneron Pharmaceuticals Unusual Options Activity ↗
 
Via Benzinga
News headline image
MAIA Biotechnology Touts Positive Data From Healthy Volunteer Study Of Potential Lung Cancer Candidate ↗
 
Via Benzinga
News headline image
Regeneron Pharmaceuticals Unusual Options Activity For April 05 ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today ↗
 
Via Benzinga
News headline image
JP Morgan Maintains Overweight Rating for Regeneron Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Investing $1,000 In These 2 Top Stocks Would Be a Great Move ↗
Both have beaten the market over the past year. 
Via The Motley Fool
News headline image
2 Top Growth Stocks That Could Soar This Spring ↗
Exciting news on the way for both of these companies could send their stock prices screaming higher. 
Via The Motley Fool
News headline image
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags ↗
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners. 
Via Talk Markets
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
NVIDIA To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday ↗
Benchmark cut the price target for CuriosityStream Inc. (NASDAQ: CURI) from $8 to $4. Benchmark analyst Daniel Kurnos maintained a Buy rating. CuriosityStream shares dropped 22.5% to $1.24 in... 
Via Benzinga
News headline image
Regeneron Pharmaceuticals Unusual Options Activity For March 28 ↗
 
Via Benzinga
News headline image
Analyst Ratings for Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Baird Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity? ↗
Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease. 
Via The Motley Fool
News headline image
Regeneron Pharmaceuticals, Hess And 1 Of World's Biggest Bank: CNBC's 'Final Trades' ↗
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management said she is sticking with Regeneron Pharmaceuticals, Inc. 
Via Benzinga
News headline image
UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug ↗
UNITY Biotechnology Inc (NASDAQ: UBX) announced results from Part A of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not achieving optimum... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 27, 2023 ↗
 
Via Benzinga
News headline image
Pinterest To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Monday ↗
UBS cut the price target for DISH Network Corporation (NASDAQ: DISH) from $27 to $10. UBS analyst John Hodulik downgraded the stock from Buy to Neutral. DISH Network shares fell 2.1% to $8.57 in... 
Via Benzinga
News headline image
Could This Label Expansion Be a Growth Catalyst for Sanofi Stock? ↗
Sanofi and Regeneron's mega-blockbuster drug could soon be approved in the U.S. for yet another indication. 
Via The Motley Fool
News headline image
Wall Street Has High Hopes for These 2 Nasdaq Stocks ↗
Even in choppy markets, there are smart investments you can make. 
Via The Motley Fool
News headline image
Stock Market Split As Fed Hikes Rates, Banks Keep Tumbling; Nvidia, On Holding In Focus: Weekly Review ↗
The major indexes showed volatile, divergent action. 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023 ↗
 
Via Benzinga
News headline image
Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic obstructive pulmonary disease (COPD) met... 
Via Benzinga
News headline image
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration ↗
Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday after the companies announced primary and all key secondary endpoints were met in a Phase 3 trial... 
Via Benzinga
News headline image
US Stocks On Track For Weak Start Friday Amid Renewed Banking Concerns And Contagion Fears ↗
Renewed concerns about the banking system appear to weigh on stocks, as the major index futures point to a sharply lower opening on Friday. 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.